TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection
Titel:
TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection
Auteur:
Soo, Ross Andrew de Marinis, Filippo Han, Ji-Youn Ho, James Chung-Man Martin, Emma Servidio, Leslie Sandelin, Martin Popat, Sanjay